J&J hands Arrowhead a plum $3.7B deal for hep B-plus 3 — corralling a possible game-changing RNAi drug
Two years after Arrowhead Pharmaceuticals $ARWR conceded that a substantial segment of their RNAi pipeline was hopelessly compromised and had to be jettisoned, crippling their stock price, the biotech is staging a major comeback.
In the wake of an early look at positive early returns for their hepatitis B candidate, J&J is stepping up with one of their famous licensing pacts, forking over $250 million in cash for an upfront and equity stake, seasoning it with a $50 million near-term plum and promising much, much more for a breakthrough performance in a key disease target.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
